Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine

Journal of Neurosurgery

Volumn 102, Issue 6, 2005, Pages 1055-1068

  Rodak, Roksana ^b   Kubota, Hisashi ^b   Ishihara, Hideyuki ^b   Eugster, Hans Pietro ^b   Könü, Dilek ^b   Möhler, Hanns ^b   Yonekawa, Yasuhiro ^b   Frei, Karl ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

Generation of reactive oxygen intermediates; Malignant glioma; Programmed cell death; Taurolidine; Vascular endothelial growth factor

Indexed keywords

ACETYLCYSTEINE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; DNA FRAGMENT; REACTIVE OXYGEN METABOLITE; TAUROLIDINE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYL ALANYL ASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; CASPASE; COL11A2 PROTEIN, HUMAN; COLLAGEN TYPE 11; CYSTEINE PROTEINASE INHIBITOR; DRUG DERIVATIVE; FAS LIGAND; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; PEPTIDE CHLOROMETHYL KETONE; PHOSPHATIDYLSERINE; TAURINE; THIADIAZINE DERIVATIVE; VASCULOTROPIN A;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; GLIOMA CELL; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOLECULAR CLONING; PRIORITY JOURNAL; BRAIN TUMOR; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; GLIOMA; METABOLISM; MITOCHONDRION; PHYSIOLOGY; TUMOR CELL LINE;

ACETYLCYSTEINE; AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CASPASES; CELL LINE, TUMOR; COLLAGEN TYPE XI; CYSTEINE PROTEINASE INHIBITORS; FAS LIGAND PROTEIN; GENE EXPRESSION; GLIOMA; HUMANS; MEMBRANE GLYCOPROTEINS; MITOCHONDRIA; PHOSPHATIDYLSERINES; POLY(ADP-RIBOSE) POLYMERASES; REACTIVE OXYGEN SPECIES; TAURINE; THIADIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23144431723     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2005.102.6.1055     Document Type: Article

References (58)

1. Bakondi E, Bai P, Szabo EE, Hunyadi J, Gergely P, Szabo C, et al: Detection of poly (ADP-ribose) polymerase activation in oxidatively stressed cells and tissues using biotinylated NAD substrate. J Histochem Cytochem 50:91-98, 2002
2. Bedrosian I, Sofia RD, Wolff SM, Dinarello CA: Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine 3:568-575, 1991
3. Belmokhtar CA, Hillion J, Ségal-Bendirdjian E: Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms. Oncogene 20:3354-3362, 2001
4. Boya P, Andreau K, Poncet D, Zamzami N, Perfettini JL, Metivier D, et al: Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med 197:1323-1334, 2003
5. Braun JS, Novak R, Murray PJ, Eischen CM, Susin SA, Kroemer G, et al: Apoptosis-inducing factor mediates microglial and neuronal apoptosis caused by pneumococcus. J Infect Dis 184:1300-1309, 2001
6. Browne MK: Pharmacological and clinical studies on taurolin, in Bruckner WL, Pfirrmann RW (eds): Taurolin: ein neues Konzept zur antimikrobiellen Chemotherapie Chirurgischer Infektionen. Baltimore: Urban & Schwarzenberg, 1985, pp 51-63
7. Browne MK, Leslie GB, Pfirrmann RW, Brodhage H: The in vitro and in vivo activity of taurolin against anaerobic pathogenic organisms. Surg Gynecol Obstet 145:842-846, 1977
8. Bursch W: The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Differ 8:569-581, 2001
9. Calabresi P, Goulette FA, Darnowski JW: Taurolidne: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 61:6816-6821, 2001
10. Castagne V, Clarke PG: Axotomy-induced retinal ganglion cell death in development: its time-course and its diminution by antioxidants. Proc R Soc Lond B Biol Sci 263:1193-1197, 1996
11. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CCY, et al: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 93:8502-8507, 1996
12. 2 injury. J Neurochem 82:19-29, 2002
13. Cornali E, Zietz C, Benelli R, Weninger W, Masiello L, Breier G, et al: Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 149:1851-1869, 1996
14. Date T, Belanger AJ, Mochizuki S, Sullivan JA, Liu LX, Scaria A, et al: Adenovirus-mediated expression of p53 prevents hypoxia/reoxygenation injury by reducing reactive oxygen species and caspase activity. Cardiovasc Res 55:309-319, 2002
15. De Flora S, Izzotti A, D'Agostini F, Balansky RM: Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis 22:999-1013, 2001
16. Filipovic DM, Meng X, Reeves WB: Inhibition of PARP prevents oxidant-induced necrosis but not apoptosis in LLC-PK1 cells. Am J Physiol 277:F428-F436, 1999
17. Frei K, Ambar B, Adachi N, Yasuhiro Y, Fontana A: Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligandmediated apoptosis. J Neuroimmunol 87:105-113, 1998
18. Friesen C, Herr I, Krammer PH, Debatin KM: Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2:574-577, 1996
19. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nuñez G, Krammer PH, Peter ME, Debatin KM: Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 57:4956-4964, 1997
20. Fulda S, Los M, Friesen C, Debatin KM: Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 76:105-114, 1998
21. Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, Debatin KM: Activation of the CD95 (APO-1/Fas) pathway in drug- and γ-irradiation- induced apoptosis of brain tumor cells. Cell Death Differ 5:884-893, 1998
22. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM: The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57:3823-3829, 1997
23. Galanis E, Buckner J: Chemotherapy for high-grade gliomas. Br J Cancer 82:1371-1380, 2000
24. Gidley MJ, Sanders JK, Myers ER, Allwood MC: The mode of antibacterial action of some "masked" formaldehyde compounds. FEBS Lett 127:225-227, 1981
25. Gorman SP, McCafferty DF, Woolfson AD, Junes DS: Electron and light microscope observations of bacterial cell surface effects due to taurolidine treatment. Lett Appl Microbiol 4:103-109, 1987
26. Gorman SP, McCafferty DF, Woolfson AD, Junes DS: Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with taurolin, a novel antimicrobial agent. J Appl Bacteriol 62:315-320, 1987
27. Green D, Kroemer G: The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol 8:267-271, 1998
28. Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS: Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 59:1592-1598, 1999
29. Han Z, Ribbizi I, Pantazis P, Wyche J, Darnowski J, Calabresi P: The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. Anticancer Res 22:1959-1964, 2002
30. Jaattela M, Tschopp J: Caspase-independent cell death in T lymphocytes. Nat Immunol 4:416-423, 2003
31. Jabs T: Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Biochem Pharmacol 57:231-245, 1999
32. Jones BE, Lo CR, Liu H, Pradhan Z, Garcia L, Srinivasan A, et al: Role of caspases and NF-kappaB signaling in hydrogen peroxide- and superoxide-induced hepatocyte apoptosis. Am J Physiol Gastrointest Liver Physiol 278:G693-G699, 2000
33. Kanegane H, Wang F, Tosato G: Virus-cell interactions in a natural killer-like cell line from a patient with lyphoblastic lymphoma. Blood 88:4667-4675, 1996
34. Kaneto H, Kajimoto Y, Miyagawa J, Matsuoka T, Fujitani Y, Umayahara Y, et al: Beneficial effects of antioxidants in diabetes: possible protection of pancreatic (β-cells against glucose toxicity. Diabetes 48:2398-2406, 1999
35. Kanazawa T, Kondo Y, Ito H, Kondo S, Germano I: Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 63:2103-2108, 2003
36. Kimmel DW, Shapiro JR, Shapiro WR: In vitro drug sensitivity testing in human gliomas. J Neurosurg 66:161-171, 1987
37. Latour I, Leunda-Casi A, Denef JF, Buc Calderon P: Activation of poly(ADP-Ribose)Polymerase in rat hepatocytes does not contribute to their cell death by oxidative stress. Exp Cell Res 254:173-179, 2000
38. Leaper DJ: Prevention of peritoneal adhesion after thermal injury using noxythiolin and taurolin, in Brückner WL, Pfirrmann RW (eds): A New Concept in Antimicrobial Chemotherapy for Surgical Infection. Baltimore: Urban & Schwarzenberg, 1985, pp 115-119
39. Leist M, Jaattela M: Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2:1-10, 2001
40. Li H, Zhu H, Xu CJ, Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501, 1998
41. Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS: Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA 94:979-984, 1997
42. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT: Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst 89:783-789, 1997
43. Monson JRT, Ramsey PS, Donohue JH: Taurolidine inhibits tumor necrosis factor (TNF) toxicity-new evidence of TNF and endotoxin synergy. Eur J Surg Oncol 19:226-231, 1993
44. Nagata S: Apoptosis by death factor. Cell 88:355-365, 1997
45. Nitsche D, Jostarndt L, Besch H, Hamelmann H: Investigations of endotoxin inactivation in plasma. Preliminary results of a controlled randomized study of taurolidine as a supplementary therapeutic agent in septicemia, in Schweiberer L, Eitel F (eds): Emergency Surgery Trends. Techniques, Results. Proceedings of the 7th International Congress of Emergency Surgery. Munich: Zuckschwerdt, 1985, p 185
46. Pfirrmann RW, Leslie GB: The anti-endotoxin activity of Taurolin in experimental animals. J Appl Bacteriol 46:97-102, 1979
47. Pollman MJ, Hall JL, Gibbons GH: Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury. Influence of redox state and cell phenotype. Circ Res 84:113-121, 1999
48. Ribizzi I, Darnowski JW, Goulette FA, Akhtar MS, Chatterjee D, Calabresi P: Taurolidine: preclinical evaluation of a novel, highly selective, agent for bone marrow purging. Bone Marrow Transplant 29:313-319, 2002
49. Shibuya M: Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 67:281-316, 1995
50. Solary E, Micheau O, Dimanche-Boitrel MT, Martin F: La systeme Fas/Fas-ligand: implications dans la reponse immunitaire antitumorale et dans l'activite des agents cytotoxiques. Bull Cancer 85:685-694, 1998
51. Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Jänisch W, et al: Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res 24: 1143-1147, 2004
52. Stendel R, Scheurer L, Schlatterer K, Gminski R, Möhler H: Taurolidine-Fibrin-Sealant-Matrix using spray application for local treatment of brain tumors. Anticancer Res 24:631-638, 2004
53. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al: Molecular characterization of mitochondrial apoptosisinducing factor. Nature 397:441-446, 1999
54. Vajkoczy P, Menger MD: Vascular microenvironment in gliomas. J Neurooncol 50:99-108, 2000
55. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V. J Immunol Methods 184:39-51, 1995
56. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Introduction and modulation of sensitivity by cytokines. J Clin Invest 94:954-964, 1994
57. Yao KC, Komata T, Kondo Y, Kanazawa T, Kondo S, Germano IM: Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy. J Neurosurg 98:378-384, 2003
58. Yao Y, Kubota T, Sato K, Kitai R, Takeuchi H, Arishima H: Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours. Acta Neurochir 143:159-166, 2001